New drug targets 'Undruggable' cancer mutation in early human trial
Disease control
Recruiting now
This study is testing a new drug called FMC-376 for people with advanced solid tumors that have a specific genetic change called KRAS G12C. The main goals are to find a safe and effective dose and to see if the drug can shrink or control tumors. It is for patients whose cancer ha…
Phase: PHASE1, PHASE2 • Sponsor: Frontier Medicines Corporation • Aim: Disease control
Last updated Mar 10, 2026 12:53 UTC